Strand Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
123
- Latest Deal Type
-
2ndary - Private
- Investors
-
29
Strand Therapeutics General Information
Description
Developer of a medicine infrastructure platform intended to create medicines that respond to disease signals in real-time. The company's platform helps create programmable messenger ribonucleic acid therapies where synthetic biology meets programmable biology for logic-controlled expression, precision delivery, and control over therapeutic outcomes, enabling patients to have improved treatment options for cancer and other life-threatening diseases.
Contact Information
Website
www.strandtx.comCorporate Office
- 20 Overland Street
- Suite A
- Boston, MA 02215
- United States
Corporate Office
- 20 Overland Street
- Suite A
- Boston, MA 02215
- United States
Strand Therapeutics Timeline
Strand Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 14. Later Stage VC (Series B) | 07-Aug-2025 | Completed | Clinical Trials - Phase 1 | |||
| 13. Later Stage VC (Series A) | 28-Nov-2022 | Completed | Clinical Trials - Phase 1 | |||
| 12. Grant | 17-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 15-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 01-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Accelerator/Incubator | 01-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 8. Debt - PPP | 12-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Seed Round | 04-Jun-2019 | $5.89M | $5.89M | Completed | Clinical Trials - Phase 1 | |
| 6. Accelerator/Incubator | 15-May-2019 | Completed | Clinical Trials - Phase 1 |
Strand Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | 7,257,044 | $0.000010 | $5.81 | $5.81 | 1x | $5.81 | 13.82% | |
| Seed | 5,886,624 | $0.000010 | $1 | $1 | 1x | $1 | 11.21% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Strand Therapeutics Comparisons
Industry
Financing
Details
Strand Therapeutics Competitors (53)
One of Strand Therapeutics’s 53 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Strand Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Strand Therapeutics Patents
Strand Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178331-A1 | Synthetic internal ribosome entry sites and uses thereof | Pending | 21-Feb-2025 | ||
| WO-2026165118-A1 | Polynucleotides comprising detargeting sensors and uses thereof | Pending | 29-Jan-2025 | ||
| AU-2025255123-A1 | Human-derived synthetic regulators and uses thereof | Pending | 12-Apr-2024 | ||
| WO-2025217591-A1 | Human-derived synthetic regulators and uses thereof | Pending | 12-Apr-2024 | ||
| AU-2024393476-A1 | Circular rna synthesis | Pending | 04-Dec-2023 | C12N15/64 |
Strand Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Strand Therapeutics Investors (29)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alderline Group | Family Office | Minority | ||
| Alix Ventures | Venture Capital | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Atinum Investment | Venture Capital | Minority | ||
| Gradiant | VC-Backed Company | Minority |
Strand Therapeutics FAQs
-
When was Strand Therapeutics founded?
Strand Therapeutics was founded in 2017.
-
Where is Strand Therapeutics headquartered?
Strand Therapeutics is headquartered in Boston, MA.
-
What is the size of Strand Therapeutics?
Strand Therapeutics has 123 total employees.
-
What industry is Strand Therapeutics in?
Strand Therapeutics’s primary industry is Drug Discovery.
-
Is Strand Therapeutics a private or public company?
Strand Therapeutics is a Private company.
-
What is Strand Therapeutics’s current revenue?
The current revenue for Strand Therapeutics is .
-
How much funding has Strand Therapeutics raised over time?
Strand Therapeutics has raised $256M.
-
Who are Strand Therapeutics’s investors?
Alderline Group, Alix Ventures, Amgen Ventures, Atinum Investment, and Gradiant are 5 of 29 investors who have invested in Strand Therapeutics.
-
Who are Strand Therapeutics’s competitors?
Relay Therapeutics, etherna, WaVe Life Sciences, Apeptico, and Adaptimmune Therapeutics are some of the 53 competitors of Strand Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
